# Altheos

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/altheos

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: altheos.net
- Total disclosed funding: $43M
- Latest round: Series A (Feb 23, 2012)
- Investors on record: 6

## About

Altheos is a biotechnology company focused on developing innovative therapies to address unmet medical needs, particularly in the field of autoimmune diseases and cancer.Altheos is engaged in the development of therapies that target autoimmune diseases and cancer. The company is headquartered in San Francisco, US. Altheos raised USD 16.50 mn in Series A funding, with participation from investors such as Bay City Capital, Canaan Partners, and Novo Nordisk A/S. The total amount raised by the company is USD 16.50 mn. The most recent funding round occurred on February 23, 2012.Altheos specializes in innovative therapeutic solutions targeting autoimmune diseases and cancer, focusing on the development of effective treatment protocols that comply with international health standards. Their products aim to provide healthcare professionals with advanced tools for patient care.Revenue for Altheos is primarily generated through the development and commercialization of its therapeutic products, which are designed to meet the precise needs of healthcare providers and patients. The company's revenue structure is established through strategic partnerships and collaborations within the healthcare sector, ensuring a consistent influx of financial support to sustain its operations.Altheos plans to leverage its recent funding of USD 16.50 mn from its Series A round to enhance its research and development initiatives. The company is designing new therapeutic products aimed at expanding its portfolio in autoimmune and cancer treatment. Altheos is also exploring opportunities for market expansion beyond the US, targeting regions such as Europe and Asia by 2015, to increase accessibility to its innovative therapies.

## Funding rounds

- Series A, Feb 23, 2012, $17M — Canaan Partners, Bay City Capital, Novo Nordisk A/S
- Series A, Jul 22, 2011, $6.6M — Canaan Partners, Novo Holdings, Bay City Capital
- Series A, Apr 5, 2010, $20M — Canaan Partners, Bay City Capital, Novo Nordisk A/S, Life Science Angels, Inc., Atheneos Ventures

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series A
- Novo Nordisk A/S — Series A
- Life Science Angels, Inc. — Series A
- Atheneos Ventures (https://capitalatlas.ai/funds/atheneos-ventures) — Series A
- Novo Holdings — Series A